English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17933/22952 (78%)
Visitors : 7336583      Online Users : 493
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/17966


    Title: Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma
    Authors: Yu, Yung-Luen
    Su, Kuo-Jung
    Hsieh, Yi-Hsien
    Lee, Hsiang-Lin
    Chen, Tzy-Yen
    Hsiao, Pei-Ching
    Yang, Shun-Fa
    Contributors: 中山醫大
    Date: 2013
    Issue Date: 2017-07-13T08:26:10Z (UTC)
    Publisher: PLoS One
    ISSN: 1932-6203
    Abstract: Abstract

    Background

    The enhancer of zeste 2 (EZH2) gene encodes the histone methyltransferase that is the catalytic component of the polycomb repressive complex-2, which initiates epigenetic silencing of genes. The expression level of EZH2 in hepatocellular carcinoma (HCC) is highly correlated with tumor progression; however, it has not been determined if specific EZH2 genetic variants are associated with the risk of HCC. This study investigated the potential associations of EZH2 single-nucleotide polymorphisms with HCC susceptibility and its clinicopathologic characteristics.

    Methodology/Principal Findings

    A total of 220 HCC patients and 552 cancer-free controls were analyzed for four EZH2 single-nucleotide polymorphisms (rs6950683, rs2302427, rs3757441, and rs41277434) using real-time PCR genotyping. After adjusting for other co-variants, the individuals carrying at least one C allele at EZH2 rs6950683 and rs3757441 had a 0.611-fold and a 0.660-fold lower risk of developing HCC than did wild-type (TT) carriers, respectively. The CCCA or CCTA haplotype among the four EZH2 sites (rs6950683, rs2302427, rs3757441, and rs41277434), respectively, was also associated with a reduced risk of HCC. Furthermore, HCC patients who carried at least one C allele at rs6950683 or rs3757441 had a higher lymph–node-metastasis risk but a lower liver-cirrhosis risk than did patients carrying the wild-type allele.

    Conclusions

    The rs6950683 and rs3757441 polymorphic genotypes of EZH2 might contribute to the prediction of susceptibility to and pathological development of HCC. This is the first study to provide insight into risk factors associated with EZH2 variants in carcinogenesis of HCC in Taiwan.
    URI: https://doi.org/10.1371/journal.pone.0074870
    https://ir.csmu.edu.tw:8080/ir/handle/310902500/17966
    Relation: PLoS One. 2013; 8(9): e74870.
    Appears in Collections:[醫學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML311View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback